BioAtla, Inc. (BCAB) Financials
BCAB Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 8.6 million | 45.9 million |
| Dec. 31, 2025 | 13.8 million | 50.0 million |
| Sept. 30, 2025 | 15.9 million | 47.1 million |
| June 30, 2025 | 27.1 million | 43.9 million |
BCAB Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -5.3 million | 956000 |
| Dec. 31, 2025 | -7.9 million | 1.1 million |
| Sept. 30, 2025 | -9.9 million | 1.3 million |
| June 30, 2025 | -14.1 million | 1.4 million |
BCAB Net Income
No data available :(
BCAB Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 2.0 million | 4.5 million | 6.1 million |
| Dec. 31, 2025 | 7.1 million | 4.8 million | 1.4 million |
| Sept. 30, 2025 | 8.3 million | - | 6.2 million |
| June 30, 2025 | 18.2 million | - | 6.0 million |
BCAB Shares Outstanding
BCAB Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | - | 4.6 million | 4.7 million | - |
| Dec. 31, 2025 | - | 8.0 million | 3.3 million | - |
| Sept. 30, 2025 | - | 9.5 million | 4.3 million | - |
| June 30, 2025 | 14.2 million | 13.7 million | 5.0 million | - |
BCAB Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | - | 120000 |
| Dec. 31, 2025 | 2.0 million | -806000 |
| Sept. 30, 2025 | - | 56000 |
| June 30, 2025 | - | 567000 |
BCAB
Price: $3.37
52 week price:
Earnings Per Share: -41.56 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 285700
Market Capitalization: 5.3 million